Pharmacogenetic analysis of adjuvant FOLFOX for Korean patients with colon cancer

Pharmacogenetic Assessment of Toxicity and Outcome in Patients With Metastatic Colorectal Cancer Treated With LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05

(2010) Valérie Boige et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety and tolerability of FOLFOX4 in the adjuvant treatment of colon cancer in Asian patients: The MASCOT study

(2009) Po-Huang LEE et al.   Asia-Pacific Journal of Clinical Oncology

Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer

(2009) W Chua et al.   BRITISH JOURNAL OF CANCER

Cancer Pharmacoethnicity: Ethnic Differences in Susceptibility to the Effects of Chemotherapy

(2009) P. H. O'Donnell et al.   CLINICAL CANCER RESEARCH

Racial Differences in Advanced Colorectal Cancer Outcomes and Pharmacogenetics: A Subgroup Analysis of a Large Randomized Clinical Trial

(2009) Hanna K. Sanoff et al.   JOURNAL OF CLINICAL ONCOLOGY

Initial Safety Report of NSABP C-08: A Randomized Phase III Study of Modified FOLFOX6 With or Without Bevacizumab for the Adjuvant Treatment of Patients With Stage II or III Colon Cancer

(2009) Carmen J. Allegra et al.   JOURNAL OF CLINICAL ONCOLOGY

GSTM1 and GSTT1 polymorphisms and nasopharyngeal cancer risk: an evidence-based meta-analysis

(2009) Xianlu Zhuo et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Thymidylate synthase gene variations: predictive and prognostic markers

(2009) G. Lurje et al.   MOLECULAR CANCER THERAPEUTICS

Nationwide Cancer Incidence in Korea, 2003-2005

(2009) Young-Joo Won et al.   Cancer Research and Treatment

Thymidylate synthase haplotype is associated with tumor recurrence in stage II and stage III colon cancer

(2008) Georg Lurje et al.   Pharmacogenetics and Genomics

Pharmacogenetics in colorectal cancer: a systematic review

(2008) Silvia Funke et al.   PHARMACOGENOMICS